Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Change in Account Payables: 2013-2024

Historic Change in Account Payables for Aclaris Therapeutics (ACRS) over the last 12 years, with Dec 2024 value amounting to -$4.2 million.

  • Aclaris Therapeutics' Change in Account Payables fell 4.07% to $377,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 193.91%. This contributed to the annual value of -$4.2 million for FY2024, which is 184.32% down from last year.
  • Latest data reveals that Aclaris Therapeutics reported Change in Account Payables of -$4.2 million as of FY2024, which was down 184.32% from -$1.5 million recorded in FY2023.
  • In the past 5 years, Aclaris Therapeutics' Change in Account Payables registered a high of $3.7 million during FY2021, and its lowest value of -$5.2 million during FY2020.
  • Over the past 3 years, Aclaris Therapeutics' median Change in Account Payables value was -$1.5 million (recorded in 2023), while the average stood at -$1.8 million.
  • In the last 5 years, Aclaris Therapeutics' Change in Account Payables soared by 170.03% in 2021 and then tumbled by 500.27% in 2023.
  • Yearly analysis of 5 years shows Aclaris Therapeutics' Change in Account Payables stood at -$5.2 million in 2020, then soared by 170.03% to $3.7 million in 2021, then tumbled by 89.93% to $368,000 in 2022, then crashed by 500.27% to -$1.5 million in 2023, then slumped by 184.32% to -$4.2 million in 2024.